Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Relieves pain associated with post-herpetic neuralgia. Sold as Xylocaine, Dentipatch, Lidoderm, Ztlido, Bondlido. Every FDA application for this active ingredient: 8 branded and 31 generic.
As of Nov 15, 2026, FDA lists 39 applications for Lidocaine (sold as Xylocaine, Dentipatch, Lidoderm and others), first approved May 17, 1951, with 1 new use approved and 2 published complete response letters.
First approved: May 17, 1951
Applications: 39
New uses approved: 1
Complete response letters: 2
Medicare spending, 2025: $277M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
PenlesA drug with a new additional indication and a new dosage for the relief of pain during skin laser radiation therapy. · Nitto Denko Corporation · Jun 14, 2013
PenlesA drug with a new additional indication and a new dosage for pain relief at the resection of molluscum contagiosum. · Nitto Denko Corporation · Jun 22, 2012
Clinical Trials
681 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Astrazeneca
Sun Pharma Canada
Alembic
Strides Pharma